Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer

Published:2024-01-12 Issue: Volume: Page:1-15
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Cherifi François¹²^ORCID,Da Silva Angélique³,Martins-Branco Diogo⁴^ORCID,Awada Ahmad¹,Nader-Marta Guilherme⁴

Affiliation:

1. Oncology Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium

2. Breast Cancer Unit, CLCC François Baclesse, Institut Normand du Sein, Caen, France

3. Departments of Pharmacology and Medical Oncology, Caen-Normandy University Hospital, PICARO Cardio-Oncology Program, Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE, Caen, France

4. Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (U.L.B), Brussels, Belgium

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2024.2302460

Reference120 articles.

1. Cancer burden statistics and trends across Europe | ECIS. [cited 2023 Dec 17] Available from: https://ecis.jrc.ec.europa.eu/index.php

2. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. ESMO Metastatic Breast Cancer Living Guidelines V1.1 May 2023 . [cited 2023 Aug 21]. Available from: https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline

4. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

5. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates